On March 11, 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-19) outbreak a global pandemic. Although molecular testing remains the gold standard for COVID-19 diagnosis, serological testing enables the evaluation of the immune response to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection and vaccination, and can be used to assess community viral spread. This review summarizes and analyzes the current landscape of SARS-CoV-2 testing in the United States and includes guidance on both when and why it is important to use direct pathogen detection and/or serological testing. The usefulness of monitoring humoral and cellular immune responses in infected and vaccinated patients is also addressed. Finally, this review considers current challenges, future perspectives for SARS-CoV-2 testing, and how diagnostics are being adapted as the virus evolves.
Get full access to this article
View all access options for this article.
References
1.
360Dx. PerkinElmer's Euroimmun Gets CE Mark SARS-CoV-2 Antibody Test. https://www.360dx.com/immunoassays/perkinelmers-euroimmun-gets-ce-mark-sars-cov-2-antibody-test#.YLATyqj0nIU (Last accessed on June7, 2021).
2.
ArenaF, PolliniS, RossoliniGM, et al.Summary of the available molecular methods for detection of SARS-CoV-2 during the ongoing pandemic. Int J Mol Sci, 2021; 22:1298.
3.
AstutiI, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab Syndr, 2020; 14:407–412.
4.
BattyCJ, HeiseMT, BachelderEM, et al.Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Adv Drug Deliv Rev, 2021; 169:168–189.
5.
BenoitJL, BenoitSW, RoseJ, et al.Assessment of immune response against SARS-CoV-2 at emergency department evaluation in COVID-19 patients. J Lab Precis Med, 2020; 5:33.
6.
BentonDJ, WrobelAG, XuP, et al.Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature, 2020; 588:327–330.
7.
BertolettiA, TanAT, and Le BertN. The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. Oxford Open Immunol, 2021; 2:iqab006.
8.
BoyarskyBJ, WerbelWA, AveryRK, et al.Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA, 2021; 325:2204–2206.
9.
BrandI, GilbergL, BrugerJ, et al.Broad T cell targeting of structural proteins after SARS-CoV-2 infection: High throughput assessment of T cell reactivity using an automated interferon gamma release assay. Front Immunol, 2021; 12:688436.
10.
CañetePF, and VinuesaCG. COVID-19 makes B cells forget, but T cells remember. Cell, 2020; 183:13–15.
11.
CDC. CDC Recommends Use of Johnson & Johnson's Janssen COVID-19 Vaccine Resume. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html (Last accessed on August27, 2021).
12.
CDC. Human coronavirus types. https://stacks.cdc.gov/view/cdc/84531 (Last accessed on June27, 2021).
13.
CDC. Interim Guidance for Antigen Testing for SARS-CoV-2. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html (Last accessed on August27, 2021).
14.
CDC. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine—United States, February 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7009e4.htm?s_cid=mm7009e4_w (Last accessed on March12, 2021).
15.
CDC. COVID data tracker weekly review. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html (Last accessed on August28, 2021).
16.
CDC. Delta Variant: What We Know About the Science https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html (Last accessed on August27, 2021).
17.
CDC. Different COVID-19 Vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html (Last accessed on June27, 2021).
18.
CDC. Frequently Asked Questions about Coronavirus (COVID-19) for Laboratories. https://www.cdc.gov/coronavirus/2019-ncov/lab/faqs.html#Interpreting-Results-of-Diagnostic-Tests (Last accessed on August24, 2021).
CDC. When You've Been Fully Vaccinated https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html (Last accessed on August27, 2021).
21.
CevikM, KuppalliK, KindrachukJ, et al.Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ, 2020; 371:m3862.
22.
CevikM, TateM, LloydO, et al.SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe, 2021; 2:e13–e22.
23.
CheX-Y, QiuL-W, PanY-X, et al.Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome. J Clin Microbiol, 2004; 42:2629–2635.
24.
ChenZ, and John WherryE. T cell responses in patients with COVID-19. Nat Rev Immunol, 2020; 20:529–536.
25.
ClaphamH, HayJ, RoutledgeI, et al.Seroepidemiologic study designs for determining SARS-COV-2 transmission and immunity. Emerg Infect Dis J, 2020; 26:1978.
26.
DobañoC, SantanoR, JiménezA, et al.Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies. Transl Res, 2021; 232:60–74.
27.
DuanK, LiuB, LiC, et al.Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A, 2020; 117:9490–9496.
28.
DuttaNK, MazumdarK, and GordyJT. The nucleocapsid protein of SARS-CoV-2: a target for vaccine development. J Virol, 2020; 94:e00647-20.
29.
EmmerichP, von PosselR, HemmerCJ, et al.Longitudinal detection of SARS-CoV-2-specific antibody responses with different serological methods. J Med Virol, 2021; 93:5816–5824.
30.
EUROIMMUN. SARS-CoV-2 Immunoblot from EUROIMMUN https://www.coronavirus-diagnostics.com/antibody-detection-immunoblot.html (Last accessed on June6, 2021).
FDA. Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination: FDA Safety Communication. https://www.fda.gov/medical-devices/safety-communications/antibody-testing-not-currently-recommended-assess-immunity-after-covid-19-vaccination-fda-safety?utm_medium=email&utm_source=govdelivery (Last accessed on June27, 2021).
33.
FDA. FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review. https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough (Last accessed on September1, 2021).
34.
FDA. FDA Approves First COVID-19 Vaccine https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine (Last accessed on August23, 2021).
35.
FDA. In Vitro Diagnostics EUAs—Antigen Diagnostic Tests for SARS-CoV-2. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2 (Last accessed on November16, 2021).
36.
FDA. In Vitro Diagnostics EUAs—Molecular Diagnostic Tests for SARS-CoV-2. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular (Last accessed on November16, 2021).
37.
FDA. In Vitro Diagnostics EUAs—Serology and Other Adaptive Immune Response Tests for SARS-CoV-2. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2#individual-serological (Last accessed on November16, 2021).
38.
FDA. Investigational COVID-19 Convalescent Plasma. Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-covid-19-convalescent-plasma (Last accessed on June27, 2021).
39.
FIND. SARS-CoV-2 DIAGNOSTIC PIPELINE. https://www.finddx.org/covid-19/pipeline/?section=molecular-assays#diag_tab (Last accessed on June27, 2021).
40.
FolegattiPM, EwerKJ, AleyPK, et al.Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, 2020; 396:467–478.
41.
GasparEB, and De GaspariE. Avidity assay to test functionality of anti-SARS-Cov-2 antibodies. Vaccine, 2021; 39:1473–1475.
42.
GasserR, CloutierM, PrévostJ, et al.Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. Cell Rep, 2021; 34:108790.
43.
GoyalA, ReevesDB, Cardozo-OjedaEF, et al.Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events. Elife, 2021; 10:e63537.
44.
GrandjeanL, SasoA, TorresA, et al. Humoral response dynamics following infection with SARS-CoV-2. medRxiv, 2020:2020.2007.2016.20155663.
45.
GrifoniA, SidneyJ, ZhangY, et al.A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe, 2020; 27:671–680.e672.
46.
GrifoniA, WeiskopfD, RamirezSI, et al.Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell, 2020; 181:1489–1501.e1415.
47.
GuoL, RenL, YangS, et al.Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis, 2020; 71:778–785.
48.
HanMS, ByunJ-H, ChoY, et al.RT-PCR for SARS-CoV-2: quantitative versus qualitative. Lancet Infect Dis, 2021; 21:165.
49.
HarveyWT, CarabelliAM, JacksonB, et al.SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol, 2021; 19:409–424.
50.
HirotsuY, MaejimaM, ShibusawaM, et al.Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients. Int J Infect Dis, 2020; 99:397–402.
51.
HuangAT, Garcia-CarrerasB, HitchingsMDT, et al.A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun, 2020; 11:4704.
52.
IDSA. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics (Last accessed on January17, 2021).
53.
IDSA. Convalescent Plasma. https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-interventions/convalescent-plasma (Last accessed on June7, 2021).
54.
InfantinoM, GrossiV, LariB, et al.Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J Med Virol, 2020; 92:1671–1675.
55.
IshoB, AbeKT, ZuoM, et al.Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol, 2020; 5:eabe5511.
56.
IyerAS, JonesFK, NodoushaniA, et al.Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol, 2020; 5:eabe0367.
57.
JacksonLA, AndersonEJ, RouphaelNG, et al.An mRNA Vaccine against SARS-CoV-2—preliminary Report. N Engl J Med, 2020; 383:1920–1931.
58.
Janseen. Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision. https://www.janssen.com/johnson-johnson-single-shot-covid-19-vaccinations-resume-us-all-adults-aged-18-and-older-following (Last accessed on September1, 2021).
59.
Janssen. Duration of Response—Antibody Persistency. https://www.janssenmd.com/janssen-covid19-vaccine/clinical-data/efficacy/duration-of-response-antibody-persistency (Last accessed on June21, 2021).
60.
JiangH-W, LiY, ZhangH-N, et al. Global profiling of SARS-CoV-2 specific IgG/IgM responses of convalescents using a proteome microarray. medRxiv, 2020:2020.2003.2020.20039495.
61.
JinY, WangM, ZuoZ, et al.Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. Int J Infect Dis, 2020; 94:49–52.
62.
JoyntGM, and WuWKK. Understanding COVID-19: what does viral RNA load really mean?. Lancet Infect Dis, 2020; 20:635–636.
63.
KanekoN, KuoH-H, BoucauJ, et al.Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell, 2020; 183:143–157.e113.
64.
KatzMH. Challenges in testing for SARS-CoV-2 among patients who recovered From COVID-19. JAMA Intern Med, 2021; 181:704–705.
65.
KawasujiH, TakegoshiY, KanedaM, et al.Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. PLoS One, 2020; 15:e0243597.
66.
KlinglerJ, WeissS, ItriV, et al.Role of IgM and IgA antibodies in the neutralization of SARS-CoV-2. medRxiv, 2020; DOI: 10.1101/2020.08.18.20177303.
67.
KubinaR, and DziedzicA. Molecular and serological tests for COVID-19 a comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics. Diagnostics (Basel), 2020; 10:434.
68.
LangeA, BorowikA, BocheńskaJ, et al.Immune response to COVID-19 mRNA vaccine—a pilot study. Vaccines (Basel), 2021; 9:488.
69.
LauerSA, GrantzKH, BiQ, et al.The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med, 2020; 172:577–582.
70.
Le BertN, TanAT, KunasegaranK, et al.SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature, 2020; 584:457–462.
71.
LeeWS, WheatleyAK, KentSJ, et al.Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol, 2020; 5:1185–1191.
72.
LiB, DengA, LiK, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv, 2021:2021.2007.2007.21260122.
73.
LiG, ChenX, and XuA. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med, 2003; 349:508–509.
74.
LiottiFM, MenchinelliG, MarchettiS, et al.Assessment of SARS-CoV-2 RNA test results among patients who recovered from COVID-19 with prior negative results. JAMA Intern Med, 2021; 181:702–704.
75.
LippiG, HenryBM, and PlebaniM. Anti-SARS-CoV-2 antibodies testing in recipients of COVID-19 vaccination: why, when, and how?. Diagnostics, 2021; 11:941.
76.
LiuL, LiuW, WangS, et al.A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. BMJ, 2020; 22:206–211.
77.
LiuW, LiuL, KouG, et al.Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2. J Clin Microbiol, 2020; 58:e00461-20.
78.
LogunovDY, DolzhikovaIV, ZubkovaOV, et al.Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet, 2020; 396:887–897.
79.
MaH, ZengW, HeH, et al.Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol, 2020; 17:773–775.
80.
MallettS, AllenAJ, GraziadioS, et al.At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC Med, 2020; 18:346.
81.
MaorY, CohenD, ParanN, et al.Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine, 2020; 26:100525.
82.
MattiuzziC, HenryBM, and LippiG. Making sense of rapid antigen testing in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics. Diagnosis, 2021; 8:27–31.
83.
MittalA, ManjunathK, RanjanRK, et al.COVID-19 pandemic: insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLoS Pathog, 2020; 16:e1008762.
84.
Moderna. Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). https://www.fda.gov/media/144637/download (Last accessed on June27, 2021).
85.
MugeC, KrutikaK, JasonK, et al.Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ, 2020; 371:m3862.
86.
MusserJM, ChristensenPA, OlsenRJ, et al. Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. medRxiv, 2021:2021.2007.2019.21260808.
87.
OkbaNMA, MüllerMA, LiW, et al.Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. EID J, 2020; 26:1478–1488.
88.
ÖrdM, FaustovaI, and LoogM. The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV. Sci Rep, 2020; 10:16944.
89.
Ourwordindata. Coronavirus (COVID-19) Vaccinations. https://ourworldindata.org/covid-vaccinations?country=USA (Last accessed on June1, 2021).
90.
PeguA, O'ConnellS, SchmidtSD, et al.Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science, 2021; 373:1372–1377.
91.
Pfizer-BioNTech. Emergency Use Authorization (EUA) of the Pfizer-Biontech Covid-19 vaccine to prevent coronavirus disease 2019 (COVID-19). https://www.fda.gov/media/144413/download (Last accessed on June27, 2021).
92.
PolandGA, OvsyannikovaIG, KennedyRB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet, 2020; 396:1595–1606.
PutcharoenO, WacharapluesadeeS, ChiaWN, et al.Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand. PLoS One, 2021; 16:e0246864.
95.
SahinU, MuikA, VoglerI, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv, 2020:2020.2012.2009.20245175.
96.
SchoemanD, and FieldingBC. Coronavirus envelope protein: current knowledge. Virol J, 2019; 16:69.
97.
SchwarzkopfS, KrawczykA, KnopD, et al.Cellular immunity in COVID-19 convalescents with PCR-confirmed infection but with undetectable SARS-CoV-2-specific IgG. Emerg Infect Dis J, 2021; 27:122.
98.
SetteA, and CrottyS. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell, 2021; 184:861–880.
99.
ShahVK, FirmalP, AlamA, et al.Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol, 2020; 11:1949.
100.
SheridanC. COVID-19 testing turns to T cells. Nat Biotechnol, 2021; 39:533–534.
101.
SoniN, PaiP, Krishna KumarGR, et al. A flow virometry process proposed for detection of SARS-CoV-2 and large-scale screening of COVID-19 cases. Future Virol, 2020:10.2217/fvl-2020-0141.
102.
SterlinD, MathianA, MiyaraM, et al.IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med, 2021; 13:eabd2223.
103.
ToKK-W, TsangOT-Y, LeungW-S, et al.Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis, 2020; 20:565–574.
104.
WajnbergA, AmanatF, FirpoA, et al.Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science, 2020; 370:1227–1230.
105.
WangW, XuY, GaoR, et al.Detection of SARS-CoV-2 in different types of clinical specimens. JAMA, 2020; 323:1843–1844.
106.
WhitemanMC, BogardusL, GiaconeDG, et al.Virus reduction neutralization test: a single-cell imaging high-throughput virus neutralization assay for dengue. Am J Trop Med Hygiene, 2018; 99:1430–1439.
107.
WHO. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance. https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays (Last accessed on June27, 2021).
108.
WHO. SARS-CoV-2 Variants. https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/ (Last accessed on December28, 2020).
109.
WHO. WHO International Standard First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human) Instructions for Use. https://nibsc.org/documents/ifu/20-136.pdf (Last accessed on March12, 2021).
110.
WölfelR, CormanVM, GuggemosW, et al.Virological assessment of hospitalized patients with COVID-2019. Nature, 2020; 581:465–469.
111.
WuF, LiuM, WangA, et al.Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med, 2020; 180:1356–1362.
112.
WuJ, LiangB, ChenC, et al.SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun, 2021; 12:1813.
113.
WuK, ChoiA, KochM, et al. Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster. medRxiv, 2021:2021.2005.2005.21256716.
114.
XiaS, LanQ, SuS, et al.The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transd Target Ther, 2020; 5:92.
115.
YahiN, ChahinianH, and FantiniJ. Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?. J Infect, 2021; 16:58.
116.
ZhaoJ, YuanQ, WangH, et al.Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis, 2020; 71:2027–2034.
117.
ZuoJ, DowellAC, PearceH, et al.Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol, 2021; 22:620–626.
